A new clinical strategy described by researchers from Texas Children's Hospital and Baylor College of Medicine aims to shorten the diagnostic delay for biliary atresia (BA), a rare infant liver disease that can rapidly progress to irreversible liver injury if not treated early. The approach, detailed in a review published March 16, 2026, in World Journal of Pediatric Surgery (DOI: 10.1136/wjps-2025-001142), pairs direct or conjugated bilirubin (DB/Bc) measurements with a feeding abdominal ultrasound exam to identify infants who need urgent evaluation while minimizing unnecessary testing.
Biliary atresia, thought to begin before birth when the extrahepatic bile ducts do not form properly, leads to bile buildup in the liver after birth, driving progressive injury. Early treatment with Kasai portoenterostomy (KP) before 30–45 days of life offers the best chance of delaying or avoiding liver transplantation, yet diagnosis is often delayed beyond 60 days because early jaundice can resemble common newborn conditions and pale stools may not appear immediately.
The proposed pathway begins with DB/Bc measurements in the newborn nursery and early outpatient visits. Evidence cited in the review shows that DB/Bc levels can be elevated within the first 24–48 hours of life in infants with BA, before clear clinical signs emerge. Primary care providers are guided to test DB/Bc at 2–4 weeks for infants with persistent jaundice, pale stools, or previous high DB/Bc results, consistent with American Academy of Pediatrics guidance.
The second step involves a feeding abdominal ultrasound exam for infants with high DB/Bc levels. Unlike traditional fasting ultrasounds, the infant feeds before or during imaging, which can make the duct at the hilum (DaH) easier to visualize. The exam also measures maximum echogenicity (MxE) near the right portal vein. In the workflow, an MxE greater than 4.0 mm or an absent DaH raises concern for BA and may prompt definitive evaluation, while other findings support continued outpatient assessment.
The authors said the strategy is designed to make early BA evaluation more actionable for the full care team, from nursery providers and primary care physicians to radiologists, hepatologists, and surgeons. They emphasized that the aim is not to replace specialists' judgment but to give clinicians clearer signals at a critical time. By sharing the pathway, they hope other centers will provide feedback and test the approach in different practice settings.
The potential implications are broad. Universal newborn DB/Bc screening could reduce diagnostic delays and address disparities in diagnosis by identifying risk before visual signs are missed or misread. The feeding ultrasound approach could make follow-up evaluation less burdensome by avoiding fasting and potentially reducing reliance on tests requiring anesthesia or invasive procedures. For families, earlier detection could mean faster treatment decisions and a better chance of preserving the native liver. Future studies will need to evaluate implementation, cost-effectiveness, and performance across multiple centers and healthcare systems.
